Senolytic Therapy to Modulate Progression of Alzheimer's Disease

NCT04063124 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Dasatinib + Quercetin

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

[object Object]